Anti-PD-1 antibodies can induce a plethora of immune-related adverse events (irAEs).

IrAEs of the skin, gastrointestinal tract, liver, endocrine and renal system were analyzed.

Diabetes mellitus, lichen planus and pancreas insufficiency due to pancreatitis were reported.

If symptoms are autoimmune-related, prompt treatment has to be initiated to reduce morbidity.

Since irAEs can start asymptomatic or with minimal symptoms, careful monitoring is essential.